dencichine

Research use only, not for human use.

Dencichine is a neurotoxic agent. Dencichine is a haemostatic agent, the hemostatic effect relates to modulation of the coagulation system, platelet aggregation and fibrinolytic system.

Dencichin, also known as β-ODAP, has been shown to alleviate metabolism disorder, improve renal function, relieve pathological alterations in the glomerulus of diabetic neuropathy in rats, decrease extracellular matrix deposition and increase the ratio of matrix metalloproteinase (MMP)-9 to tissue inhibitor of metalloproteinase (TIMP)-1 both in vivo and in vitro.

Dencichin (β-ODAP, 10 μM, 50 μM, 100 μM and 200 μM) increases HRE expression by 1.3±0.09, 2.5±0.07, 4.2±0.15 and 1.3±0.07 fold respectively compared to control. Dencichin has intermolecular interactions with PHD-2. Dencichin (10 μM, 100 μM, 1 mM) significantly inhibits cell proliferation and extracellular matrix (ECM) proteins accumulation of HBZY-1 cells, and reduces the secretion of collagen I (Col I), collagen IV (Col IV), and fibronectin (FN).

Dencichin improves metabolism disorder in diabetic nephropathy (DN) secondary to type II diabetes mellitus (DM) model. Dencichin (80, 160 mg/kg/day, p.o.) significantly prevents the up-regulation of TCH, TG, LDL, and HbAlc and the down-regulation of HDL in DN rats induced by STZ injection. Dencichin also attenuates renal injury induced in the DN secondary to type II DM model. Dencichin alleviates pancreas damage in the STZ-induced DN model. Dencichin regulates protein expression in the TGF-β/Smad signalling pathway in STZ-induced DN models.

β-ODAP | Dencichine | BRN-2259036 | Ox-Dapro

MAPK/ERK Signaling

p38 MAPK

Others

Others-Field

——

5302-45-4

176.13

C5H8N2O5

>98% (HPLC)

In Vitro:?H2O : 5 mg/mL (28.39 mM)

C([C@@H](C(=O)O)N)NC(=O)C(=O)O

Oxamic acid, (2-amino-2-carboxyethyl)-, L-

(-20℃)

With Ice Pack

≥ 2 years